Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management

(2018) Mrinal M. Patnaik et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value

(2018) Josep F. Nomdedéu et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Azacitidine Use for Myeloid Neoplasms

(2018) Riad El Fakih et al.   Clinical Lymphoma Myeloma & Leukemia

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

(2018) Hartmut Döhner et al.   LEUKEMIA

Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome

(2016) Joji Nagasaki et al.   ACTA HAEMATOLOGICA

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy

(2015) Patrick T. Griffin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

(2015) C. R. Cogle et al.   ONCOLOGIST

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

(2014) Taiga Nishihori et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role ofWT1expression

(2013) Sarah Pozzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

(2013) J F Nomdedéu et al.   LEUKEMIA

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis

(2012) You-Ying Chau et al.   TRENDS IN GENETICS

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

(2010) John F. Seymour et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size

(2010) J. Nomdedeu et al.   LEUKEMIA RESEARCH

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

WT1 monitoring in core binding factor AML: Comparison with specific chimeric products

(2009) Adriana Lasa et al.   LEUKEMIA RESEARCH

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals

(2008) Hans Beier Ommen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

(2008) D. Cilloni et al.   HAEMATOLOGICA

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

(2008) Priya Virappane et al.   JOURNAL OF CLINICAL ONCOLOGY